Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Initiates Buyback of $10M of Shares

NEW YORK (GenomeWeb News) – Qiagen said in a regulatory document today that it began buying back the euro equivalent of $10 million of its shares on Sept. 10 in the first tranche of a share repurchasing program.

The company will buy back a maximum of 750,000 shares of its common stock on the electronic trading platform of the Frankfurt Stock Exchange during the tranche, which will last until Nov. 1, Qiagen said in a document filed with the US Securities and Exchange Commission. The maximum purchase price on a per share basis will not exceed by more than 10 percent the average closing price for the last five trading days prior to the day of purchase on the exchange.

The company said during its second quarter earnings announcement that it was repurchasing up to $100 million of its shares in a new buyback program.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.